TScan Teams Up With Qiagen On T Cell COVID-19 Test

Qiagen NV and TScan Therapeutics are collaborating to develop T cell-based laboratory tests for detecting prior exposure to SARS-CoV-2 using TScan’s T-Scan T cell receptor (TCR) target discovery platform.

Under the terms of the agreement, announced on 10 November, Qiagen has secured an option to license the rights to certain immunodominant T cell targets discovered with the T-Scan system,...